Analogously to functional assays that detect MSI associated with various mutations in MMR genes in Lynch syndrome patients or that cytogenetically monitor reduced cross-link repair capacities resulting from various FA mutations, it is conceivable that a significant fraction of ovarian cancer risk can be captured by appropriate DNA repair assays (Figure 2). The gene discussed is MRC1; the disease is ovarian cancer.